Transient expression of an IL-23R extracellular domain Fc fusion protein in CHO vs. HEK cells results in improved plasma exposure
- PMID: 20045465
- DOI: 10.1016/j.pep.2009.12.015
Transient expression of an IL-23R extracellular domain Fc fusion protein in CHO vs. HEK cells results in improved plasma exposure
Abstract
Transient transfection of mammalian cells in suspension culture has recently emerged as a very useful method for production of research-scale quantities of recombinant proteins. The most commonly used cell lines for this purpose are suspension-adapted HEK and CHO cells. We report here that the plasma exposure in mice of an IL-23R extracellular domain Fc fusion protein (IL23R-Fc) differed dramatically depending on whether the protein was prepared by transient transfection of HEK or CHO cells. Specifically, IL23R-Fc expressed using CHO cells had about 30-fold higher in vivo plasma exposure compared to the HEK-expressed protein. In contrast to their differing plasma exposures, the HEK- and CHO-expressed proteins had equivalent in vitro biological activity. Characterization of the CHO- and HEK-expressed IL23R-Fc proteins indicated that the differences in in vivo plasma exposure between them are due to differential glycosylation.
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Purification of the extracellular domain of the membrane protein GlialCAM expressed in HEK and CHO cells and comparison of the glycosylation.Protein Expr Purif. 2008 Mar;58(1):94-102. doi: 10.1016/j.pep.2007.10.025. Epub 2007 Nov 7. Protein Expr Purif. 2008. PMID: 18082421
-
[Expression of human IL-35-IgG4 (Fc) fusion protein in CHO/DG44 cells].Sheng Wu Gong Cheng Xue Bao. 2009 Jan;25(1):109-15. Sheng Wu Gong Cheng Xue Bao. 2009. PMID: 19441235 Chinese.
-
Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18. J Immunol. 2010. PMID: 20083659
-
Appropriate mammalian expression systems for biopharmaceuticals.Arzneimittelforschung. 1998 Aug;48(8):870-80. Arzneimittelforschung. 1998. PMID: 9748718 Review.
-
Clinical Immunogenicity Risk Assessment for a Fusion Protein.AAPS J. 2020 Apr 3;22(3):64. doi: 10.1208/s12248-020-00447-y. AAPS J. 2020. PMID: 32246297 Review.
Cited by
-
Glycoengineering Chinese hamster ovary cells: a short history.Biochem Soc Trans. 2021 Apr 30;49(2):915-931. doi: 10.1042/BST20200840. Biochem Soc Trans. 2021. PMID: 33704400 Free PMC article. Review.
-
Interleukin 23 and autoimmune diseases: current and possible future therapies.Inflamm Res. 2020 May;69(5):463-480. doi: 10.1007/s00011-020-01339-9. Epub 2020 Mar 25. Inflamm Res. 2020. PMID: 32215665 Review.
-
Rapid Antibody Glycoengineering in CHO Cells Via RNA Interference and CGE-LIF N-Glycomics.Methods Mol Biol. 2022;2370:147-167. doi: 10.1007/978-1-0716-1685-7_7. Methods Mol Biol. 2022. PMID: 34611868
-
Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.Sci Rep. 2018 Mar 9;8(1):4241. doi: 10.1038/s41598-018-22456-w. Sci Rep. 2018. PMID: 29523796 Free PMC article.
-
Neutralizing antibodies to SARS-CoV-2 variants of concern: a pediatric surveillance study.Sci Rep. 2025 Apr 4;15(1):11588. doi: 10.1038/s41598-025-95956-1. Sci Rep. 2025. PMID: 40185990 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous